Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

36.23
+0.03000.08%
Post-market: 36.720.4900+1.35%19:23 EST
Volume:1.59M
Turnover:57.63M
Market Cap:3.50B
PE:-6.10
High:36.54
Open:36.39
Low:35.93
Close:36.20
52wk High:47.12
52wk Low:25.81
Shares:96.48M
Float Shares:92.79M
Volume Ratio:0.95
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.9427
EPS(LYR):-6.2867
ROE:-313.43%
ROA:-24.92%
PB:381.63
PE(LYR):-5.76

Loading ...

Stock Track | Ultragenyx Pharmaceutical Plummets 11.89% Pre-market on Weak Q3 Results and Royalty Sale

Stock Track
·
Nov 05

Stock Track | Ultragenyx Pharmaceutical Plummets 11.89% Pre-market on Royalty Sale and Weak Q3 Results

Stock Track
·
Nov 05

Stock Track | Ultragenyx Pharmaceutical Plunges 11.83% Pre-market Following Royalty Sale and Disappointing Q3 Results

Stock Track
·
Nov 05

TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Nov 05

Ultragenyx Pharmaceutical Q3 Net Loss Widens, Revenue Increases

MT Newswires Live
·
Nov 05

Stock Track | Ultragenyx Plunges 13.68% After Selling Additional Crysvita Royalties for $400 Million

Stock Track
·
Nov 05

Stock Track | Ultragenyx Pharmaceutical Plunges 5.98% After-Hours Following $400 Million Royalty Sale

Stock Track
·
Nov 05

Ultragenyx Reaffirms 2025 Revenue Guidance of $640 Million to $670 Million

Reuters
·
Nov 05

Ultragenyx Pharmaceutical Inc: Reaffirm 2025 Revenue Guidance

THOMSON REUTERS
·
Nov 05

Ultragenyx Sells Additional 25% Crysvita Royalty Interest to OMERS for $400 Million

Reuters
·
Nov 05

Ultragenyx Pharmaceutical Inc - Omers to Receive Additional 25% Royalty Interest on Crysvita From Jan 2028

THOMSON REUTERS
·
Nov 05

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (Burosumab) for $400 Million to Omers Life Sciences

THOMSON REUTERS
·
Nov 05

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL)

TIPRANKS
·
Oct 31

Ultragenyx announces first patient dosed in Aurora study

TIPRANKS
·
Oct 30

Ultragenyx Doses First Patient in Aurora Trial for Angelman Syndrome

Reuters
·
Oct 30

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating Gtx-102 in Additional Angelman Syndrome Genotypes and Age Groups

THOMSON REUTERS
·
Oct 30

Ultragenyx Pharmaceutical Inc. to Release Third Quarter 2025 Financial Results

Reuters
·
Oct 29

Ultragenyx Grants Restricted Stock Units to New Hires Under Inducement Plan

Reuters
·
Oct 25

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Oct 25

Press Release: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Oct 25